NASDAQ · Healthcare
Invest in Pharvaris stock from India
Indian and foreign residents can buy Pharvaris (PHVS) shares directly through Paasa.
By Paasa · Updated
Pharvaris at a glance
- Price
- $31.72-$0.01 (0.03%)
- Market cap
- $2.22B
- Day range
- $31.18 – $32.03
- P/E
- -10.37
- Dividend yield
- None
- Volume
- 839.81K
- 1 month
- -8.35%
- 6 months
- +12.28%
- YTD
- +14.31%
- 1 year
- +27.13%
- 5 years
- +78.70%
Pharvaris statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | €0.0 | €0.0 | €0.0 | €0.0 | €0.0 |
| Gross profit | €0.0 | €0.0 | €0.0 | €0.0 | €0.0 |
| Operating income | −€169.8M | −€145.7M | −€96.9M | −€86.7M | −€54.1M |
| Net income | −€175.7M | −€134.2M | −€100.9M | −€76.3M | −€42.7M |
| Earnings per share | −€2.97 | −€2.48 | −€2.63 | −€2.27 | −€1.41 |
| EBITDA | −€173.3M | −€145.6M | −€99.6M | −€86.6M | −€42.3M |
| Total assets | €301.5M | €291.4M | €398.7M | €167.7M | €212.1M |
| Total debt | €776.8K | €861.5K | €238.9K | €436.8K | €250.2K |
| Cash and short-term investments | €291.7M | €280.7M | €391.2M | €161.8M | €209.4M |
| Shareholders' equity | €271.3M | €267.8M | €384.0M | €149.3M | €205.0M |
| Operating cash flow | −€137.1M | −€120.1M | −€93.0M | −€67.2M | −€44.6M |
| Free cash flow | −€137.2M | −€120.7M | −€93.1M | −€67.3M | −€44.7M |
| Capital expenditure | −€164.6K | −€538.1K | −€90.0K | −€124.3K | −€130.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Spyre Therapeutics | SYRE | $84.72 | $7.36B |
| Vera Therapeutics | VERA | $32.38 | $2.32B |
| BioCryst Pharmaceuticals | BCRX | $8.27 | $2.10B |
| Immunome | IMNM | $21.89 | $2.09B |
| Zymeworks | ZYME | $27.20 | $2.00B |
| Intellia Therapeutics | NTLA | $12.03 | $1.68B |
| Maze Therapeutics | MAZE | $27.02 | $1.50B |
| ORIC Pharmaceuticals | ORIC | $13.37 | $1.38B |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- $42.00
- High
- $79.00
- Median
- $62.00
- Consensus
- $60.75
Ratings: 13 buy · 1 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Pharvaris from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search PHVS and buy
Find Pharvaris by name or by its ticker, PHVS, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in Pharvaris from India
What Pharvaris does
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immedia… Pharvaris operates in the Biotechnology industry within the Healthcare sector.
Hold a dollar asset
Pharvaris shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one Pharvaris share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Pharvaris stock from India?
Yes. Indian residents and NRIs can buy Pharvaris (PHVS) shares directly through Paasa. Pharvaris is listed on NASDAQ, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Pharvaris share?
No. You can buy part of one Pharvaris share and add to your position over time. One share is $31.72, and you can buy whole shares or any fraction; there is no minimum trade size.
How are Pharvaris dividends taxed for Indian investors?
Pharvaris trades on NASDAQ but is domiciled in Switzerland, so any withholding on its dividends follows that country's rules rather than those of the US. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Pharvaris shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.